ERBB2 and neoplasm: The 8th edition of the AJCC BC pathological prognostic staging (PPS) was first introduced into clinical use in 2017, and incorporated contemporary biological factors, including tumour grade, human epidermal growth factor receptor-2 (HER2), oestrogen receptor (ER), and progesterone receptor (PR) status into the traditional AS system5.